Efficacy News and Research

RSS

Results of ibrutinib Phase 2 study in patients with mantle cell lymphoma published in NEJM

Pharmacyclics, Inc. today announced that The New England Journal of Medicine published results of a Phase 2 study evaluating the investigational oral Bruton's tyrosine kinase inhibitor ibrutinib in patients with relapsed/refractory mantle cell lymphoma online.

20 Jun 2013

Staph-killing compound may be effective against osteomyelitis

Osteomyelitis - a debilitating bone infection most frequently caused by Staphylococcus aureus ("staph") bacteria - is particularly challenging to treat.

20 Jun 2013

Safinamide improves responder rates in fluctuating Parkinson's patients in Phase III study

Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., a pharmaceutical company strongly committed to the respiratory, primary care and CNS therapeutic areas, presented results from SETTLE Phase III study with safinamide at the 17th International Congress of Parkinson's disease and Movement Disorders, taking place from June 16 to 20, 2013, at the Sydney Convention and Exhibition Centre, Sydney, Australia.

19 Jun 2013

Ico Therapeutics completes Phase 2 iDEAL study for treatment of diabetic macular edema

iCo Therapeutics Inc. announced today that it has completed enrollment of its Phase 2 iDEAL study evaluating the efficacy and safety after repeated injections of iCo-007 in patients with Diabetic Macular Edema (DME). The study has shown a good safety profile with no drug-related serious adverse events to date.

19 Jun 2013

OHSU analysis finds previous studies have overstated effectiveness of bone growth product used in spinal surgeries

An analysis by the Evidence-based Practice Center at Oregon Health & Science University has found that previously published clinical trial studies about a controversial bone growth product used in spinal surgeries overstated the product's effectiveness.

19 Jun 2013

NIH awards $12.7M to research groups to explore new treatments for patients in eight disease areas

The National Institutes of Health has awarded $12.7 million to match nine academic research groups with a selection of pharmaceutical industry compounds to explore new treatments for patients in eight disease areas, including Alzheimer's disease, Duchenne muscular dystrophy and schizophrenia.

19 Jun 2013

UHCMC physicians design new procedure to clear blocked carotid arteries, prevent stroke

Physicians at University Hospitals Case Medical Center enrolled their first patients in the ROADSTER Study, a global, multicenter clinical trial evaluating a novel, less-invasive procedure to help clear blockages in carotid arteries and prevent strokes.

19 Jun 2013

Eylea can ease vision problems for wet AMD patients

There is no cure for age-related macular degeneration, an eye disease that is the leading cause of vision loss and blindness in older Americans. Last year, the National Institutes of Health reported that two drugs injected into the eyes, Avastin and Lucentis, eased symptoms for sufferers, especially those in the advanced, "wet" stage of the disease, when blood vessels in the eye become swollen and leak fluids in the eye.

19 Jun 2013

OncoSec Medical completes enrollment in ImmunoPulse trial for metastatic melanoma patients

OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced the completion of patient enrollment in a Phase II clinical trial of ImmunoPulse for metastatic melanoma patients.

18 Jun 2013

Bioapplications of nanoparticles: an interview with Dr Catherine Berry, University of Glasgow

These particles are all classed as inorganic particles, which can all be utilised in biomedical applications. They differ in terms of their inherent material and size dependent physiochemical properties, for example, their optical and magnetic properties.

18 Jun 2013

AtriCure's Bipolar RF Ablation System shows promising results in persistent Afib patients

A leading German cardiovascular heart center reported promising mid-term results for the surgical treatment of persistent atrial fibrillation during last week's International Society for Minimally Invasive Cardiothoracic Surgery meeting being held in Prague, Czech Republic.

18 Jun 2013

Vanda presents additional data from tasimelteon Phase III studies at ENDO 2013

Vanda Pharmaceuticals Inc. presented additional data today at ENDO 2013, the Endocrine Society's 95th Annual Meeting, demonstrating that tasimelteon can entrain (synchronize) both melatonin and cortisol rhythms.

18 Jun 2013

Santarus, Pharming Group announce FDA acceptance of RUCONEST BLA

Santarus, Inc. and Pharming Group NV today announced that the U.S. Food and Drug Administration has accepted for filing the Biologics License Application for the investigational drug RUCONEST (recombinant human C1 esterase inhibitor) 50 IU/kg.

18 Jun 2013

Vaccine given to newborns 60% effective against rotavirus in Ghana

Mayo Clinic and other researchers have shown that a vaccine given to newborns is at least 60 percent effective against rotavirus in Ghana. Rotavirus causes fever, vomiting and diarrhea, which in infants can cause severe dehydration.

18 Jun 2013

Bazedoxifene used for treating osteoporosis stops growth of breast cancer cells

A drug approved in Europe to treat osteoporosis has now been shown to stop the growth of breast cancer cells, even in cancers that have become resistant to current targeted therapies, according to a Duke Cancer Institute study.

17 Jun 2013

Transition, Lilly amend agreement to address future development of TT-401

Transition Therapeutics Inc. announced that Eli Lilly and Company has exercised its option to assume all development and commercialization rights to type 2 diabetes drug candidate TT-401.

17 Jun 2013

Genmab, ADC Therapeutics agree to develop new antibody-drug conjugate product

Genmab A/S and ADC Therapeutics Sarl, announced today an agreement to develop a new antibody-drug conjugate product combining Genmab's HuMax-TAC antibody and ADC Therapeutics' PBD-based warhead and linker technology.

17 Jun 2013

Ibrutinib monotherapy shows efficacy in patients with MCL or DLBCL

Pharmacyclics, Inc. today announced the results of two separate Phase 2 studies suggesting that ibrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, showed efficacy when used as a monotherapy in patients with relapsed/refractory mantle cell lymphoma or diffuse large B-cell lymphoma.

17 Jun 2013

Teva to present abstracts on AZILECT at MDS meeting

Teva Pharmaceutical Industries Ltd. announced today that a number of abstracts will be presented during the 17th Annual International Congress of Parkinson's Disease and Movement Disorders in Sydney, Australia, June 16-20, 2013, also known as the Movement Disorders Society.

15 Jun 2013

Research: Deep brain stimulation is associated with weight loss trend in morbidly obese patients

The first use of deep brain stimulation to the brain's so-called "feeding center" - the lateral hypothalamic area (LHA) - was associated with a weight loss trend in morbidly obese patients whose stimulation was tuned to increase metabolism with novel guidance from metabolic chamber data, according to a pilot study presented at the International Neuromodulation Society's 11th World Congress by Dr. Michael Oh of the Department of Neurosurgery at the Allegheny General Hospital in Pittsburgh, Pa.

14 Jun 2013

Efficacy News and Research

Results of ibrutinib Phase 2 study in patients with mantle cell lymphoma published in NEJM

Staph-killing compound may be effective against osteomyelitis

Safinamide improves responder rates in fluctuating Parkinson's patients in Phase III study

Ico Therapeutics completes Phase 2 iDEAL study for treatment of diabetic macular edema

OHSU analysis finds previous studies have overstated effectiveness of bone growth product used in spinal surgeries

NIH awards $12.7M to research groups to explore new treatments for patients in eight disease areas

UHCMC physicians design new procedure to clear blocked carotid arteries, prevent stroke

Eylea can ease vision problems for wet AMD patients

OncoSec Medical completes enrollment in ImmunoPulse trial for metastatic melanoma patients

Bioapplications of nanoparticles: an interview with Dr Catherine Berry, University of Glasgow

AtriCure's Bipolar RF Ablation System shows promising results in persistent Afib patients

Vanda presents additional data from tasimelteon Phase III studies at ENDO 2013

Santarus, Pharming Group announce FDA acceptance of RUCONEST BLA

Vaccine given to newborns 60% effective against rotavirus in Ghana

Bazedoxifene used for treating osteoporosis stops growth of breast cancer cells

Transition, Lilly amend agreement to address future development of TT-401

Genmab, ADC Therapeutics agree to develop new antibody-drug conjugate product

Ibrutinib monotherapy shows efficacy in patients with MCL or DLBCL

Teva to present abstracts on AZILECT at MDS meeting

Research: Deep brain stimulation is associated with weight loss trend in morbidly obese patients

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News